About this episode

The episode discusses the surge in financials ahead of bank earnings, the rapid progress of Kymera Therapeutics' Eczema drug trial, and various stock market movements including SpaceX and Coke.

Financials surging as investors countdown to second quarter bank earnings next week, expecting major growth. The traders break down what the results could mean for these names and whether banks will see major gains. Then, shares of Kymera Therapeutics soaring as its Eczema drug trial timeline moves faster than expected. The firm’s founder, president and CEO Nello Mainolfi talks trial data and where the company is heading next. Plus, SpaceX stock plummeting despite bull calls on the Street, the media market under pressure, and Coke hitting all-time highs back to its century-old IPO. Fast Money Disclaimer

People in this episode

Guest: Nello Mainolfi

Topics covered

• U.S. banking
• stock market
• Eczema drug trial
• Kymera Therapeutics
• SpaceX stock
• Coke IPO
• financial growth

Keywords

• bank earnings
• financial growth
• Kymera Therapeutics
• Eczema drug trial
• SpaceX stock
• Coke IPO
• stock market

Mentioned in this episode

Organizations: Kymera Therapeutics, SpaceX, Coke

More episodes of CNBC's "Fast Money"

• Will Markets Keep Ignoring Iran Tensions?... And The AI Race to Supremacy 7/20/26 · July 20, 2026 · 43 min
• Title: A Big Tech Pullback… And Time to Sell Tesla? 7/17/26 · July 17, 2026 · 44 min
• Netflix Earnings Results… And What’s Next for the Energy Trade 7/16/26 · July 16, 2026 · 44 min
• Apple’s Alibaba Partnership… And Making Sense of Market Volatility 7/15/26 · July 15, 2026 · 44 min
• Software Sinks After IBM Losses… And a June CPI Reversal 7/14/26 · July 14, 2026 · 43 min
• Rates Rise Ahead of Bank Earnings… And Oil Prices Surge 7/13/26 · July 13, 2026 · 44 min

Explore listener stats, chart rankings, contacts and more on the CNBC's "Fast Money" podcast page.